Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer

被引:3
|
作者
Ota, Takayo [1 ]
Miyatake, Nozomi [1 ]
Tanaka, Noriko [2 ]
Hasegawa, Yoshikazu [1 ]
Tokunaga, Masahiro [2 ]
Tsukuda, Hiroshi [1 ]
Fukuoka, Masahiro [1 ]
机构
[1] Izumi Municipal Hosp, Dept Med Oncol, 4-10-10 Fuchu, Izumi, Osaka 5940071, Japan
[2] Izumi Municipal Hosp, Dept Radiol, Izumi, Osaka, Japan
关键词
Breast cancer; disseminated carcinomatosis of the bone marrow; hormone therapy; zoledronic acid; GASTRIC-CANCER; METASTASIS; PROGNOSIS;
D O I
10.1080/09513590.2017.1393063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Disseminated carcinomatosis of the bone marrow (DCBM) is diffusely invasive bone metastasis resulting from solid tumors. DCBM is often associated with disseminated intravascular coagulation (DIC) or hemolytic anemia. Generally, DCBM treatment includes cytotoxic chemotherapy for underlying solid tumors and management of hematological conditions if present. We report a case of DCBM accompanied with DIC in hormone receptor-positive breast cancer. Due to her life-threatening condition, we used hormone therapies, not cytotoxic chemotherapies, to treat her DCBM. With zoledronic acid, her DIC and general condition gradually improved and eventually she could return to her daily life. If DCBM occurs in hormone receptor-positive breast cancer, hormone therapy can be one of the treatment choices.
引用
收藏
页码:286 / 289
页数:4
相关论文
共 50 条
  • [41] Factors associated with endocrine therapy refusal in hormone receptor-positive breast cancer patients
    Advani, Pooja P.
    Guzman, Ricardo Torres
    Verduzco, Francisco Avila
    Maita, Karla
    Garcia, John
    Eldaly, Abdullah
    Forte, Antonio
    Spaulding, Aaron
    CANCER RESEARCH, 2022, 82 (04)
  • [42] Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer
    Funda Meric-Bernstam
    Huiqin Chen
    Argun Akcakanat
    Kim-Anh Do
    Ana Lluch
    Bryan T Hennessy
    Gabriel N Hortobagyi
    Gordon B Mills
    Ana Maria Gonzalez-Angulo
    Breast Cancer Research, 14
  • [43] Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer
    Sparano, Joseph A.
    Wang, Molin
    Zhao, Fengmin
    Stearns, Vered
    Martino, Silvana
    Ligibel, Jennifer A.
    Perez, Edith A.
    Saphner, Tom
    Wolff, Antonio C.
    Sledge, George W., Jr.
    Wood, William C.
    Fetting, John
    Davidson, Nancy E.
    CANCER, 2012, 118 (23) : 5937 - 5946
  • [44] Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer
    Ahrong Ham
    Min Hwan Kim
    Gun Min Kim
    Jee Hung Kim
    Jee Ye Kim
    Hyung Seok Park
    Seho Park
    Young Up Cho
    Byeong Woo Park
    Seung Il Kim
    Joohyuk Sohn
    Breast Cancer Research and Treatment, 2020, 183 : 107 - 116
  • [45] Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer
    Meric-Bernstam, Funda
    Chen, Huiqin
    Akcakanat, Argun
    Do, Kim-Anh
    Lluch, Ana
    Hennessy, Bryan T.
    Hortobagyi, Gabriel N.
    Mills, Gordon B.
    Gonzalez-Angulo, Ana Maria
    BREAST CANCER RESEARCH, 2012, 14 (05)
  • [46] Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer
    Meric-Bernstam, Funda
    Chen, Huiqin
    Akcakanat, Argun
    Kim-Anh Do
    Lluch, Ana
    Hennessy, Bryan
    Hortobagyi, Gabriel
    Mills, Gordon
    Gonzalez-Angulo, Ana
    CANCER RESEARCH, 2012, 72
  • [47] Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer
    Hassett, Michael J.
    Hughes, Melissa E.
    Niland, Joyce C.
    Edge, Stephen B.
    Theriault, Richard L.
    Wong, Yu-Ning
    Wilson, John
    Carter, W. Bradford
    Blayney, Douglas W.
    Weeks, Jane C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5553 - 5560
  • [48] Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men
    Venigalla, Sriram
    Carmona, Ruben
    Guttmann, David M.
    Jain, Varsha
    Freedman, Gary M.
    Clark, Amy S.
    Shabason, Jacob E.
    JAMA ONCOLOGY, 2018, 4 (10)
  • [49] Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer
    Ham, Ahrong
    Kim, Min Hwan
    Kim, Gun Min
    Kim, Jee Hung
    Kim, Jee Ye
    Park, Hyung Seok
    Park, Seho
    Cho, Young Up
    Park, Byeong Woo
    Kim, Seung Il
    Sohn, Joohyuk
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (01) : 107 - 116
  • [50] Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor-Positive and Hormone Receptor-Negative Breast Cancer
    Mehta, Rita S.
    Jackson, Donna
    Schubbert, Toni
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 3067 - 3068